Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) is now available.
ImmuneOnco Biopharmaceuticals has announced the redemption of two wealth management products totaling HK$93,323,273 from Huatai Financial, resulting in an estimated unaudited gain of HK$4,730,000. The company has also subscribed to a new wealth management product worth HK$120,000,000, funded by its internal surplus cash reserves. These transactions are classified as discloseable under the Hong Kong Stock Exchange’s listing rules, requiring notification and announcement but exempt from shareholder approval.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative cancer immunotherapy products.
Average Trading Volume: 3,582,811
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.82B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.